Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Renal Cell | 13 | 2023 | 3187 | 1.630 |
Why?
|
Kidney Neoplasms | 13 | 2023 | 4282 | 1.420 |
Why?
|
Receptors, Androgen | 1 | 2023 | 1089 | 0.560 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 6 | 2022 | 11878 | 0.500 |
Why?
|
Lung Neoplasms | 4 | 2021 | 13586 | 0.410 |
Why?
|
Angiogenesis Inhibitors | 2 | 2019 | 2056 | 0.390 |
Why?
|
Radiosurgery | 1 | 2021 | 1330 | 0.390 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2016 | 454 | 0.360 |
Why?
|
Protein Kinase Inhibitors | 3 | 2022 | 5703 | 0.340 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2015 | 2521 | 0.330 |
Why?
|
Neoplasm Metastasis | 3 | 2021 | 4912 | 0.320 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2021 | 3671 | 0.300 |
Why?
|
Neoplasms, Second Primary | 1 | 2016 | 1061 | 0.300 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2016 | 5432 | 0.280 |
Why?
|
Sequence Analysis, DNA | 1 | 2018 | 4786 | 0.280 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2024 | 794 | 0.270 |
Why?
|
Immunotherapy | 2 | 2019 | 4755 | 0.260 |
Why?
|
Piperazines | 1 | 2016 | 2554 | 0.250 |
Why?
|
Pyrazoles | 1 | 2015 | 2028 | 0.240 |
Why?
|
Neoplasms | 9 | 2022 | 22371 | 0.230 |
Why?
|
Androgen Antagonists | 2 | 2023 | 1412 | 0.220 |
Why?
|
Pyridines | 1 | 2015 | 2894 | 0.220 |
Why?
|
Caregivers | 2 | 2012 | 2302 | 0.210 |
Why?
|
Androgen Receptor Antagonists | 1 | 2023 | 123 | 0.210 |
Why?
|
Prostatic Neoplasms | 5 | 2022 | 11101 | 0.200 |
Why?
|
Terminal Care | 1 | 2012 | 1770 | 0.170 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2023 | 2195 | 0.170 |
Why?
|
Camptothecin | 1 | 2023 | 600 | 0.170 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2022 | 257 | 0.170 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2022 | 325 | 0.160 |
Why?
|
Rhabdoid Tumor | 1 | 2021 | 211 | 0.160 |
Why?
|
Orotate Phosphoribosyltransferase | 1 | 2017 | 5 | 0.140 |
Why?
|
Orotidine-5'-Phosphate Decarboxylase | 1 | 2017 | 8 | 0.140 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2016 | 9419 | 0.140 |
Why?
|
Molecular Targeted Therapy | 3 | 2018 | 2830 | 0.140 |
Why?
|
Autopsy | 1 | 2021 | 1011 | 0.140 |
Why?
|
Palliative Care | 1 | 2012 | 3643 | 0.140 |
Why?
|
Retreatment | 1 | 2018 | 598 | 0.130 |
Why?
|
Androgens | 1 | 2023 | 1281 | 0.130 |
Why?
|
Immunoconjugates | 1 | 2023 | 975 | 0.130 |
Why?
|
Drug Synergism | 1 | 2019 | 1760 | 0.120 |
Why?
|
Culture Media | 1 | 2017 | 898 | 0.120 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2019 | 879 | 0.120 |
Why?
|
Humans | 34 | 2024 | 768166 | 0.120 |
Why?
|
Immunomodulation | 1 | 2018 | 549 | 0.110 |
Why?
|
Acrylamides | 1 | 2016 | 261 | 0.110 |
Why?
|
Multienzyme Complexes | 1 | 2017 | 664 | 0.110 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2022 | 1613 | 0.110 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2016 | 640 | 0.110 |
Why?
|
Aged, 80 and over | 9 | 2023 | 59629 | 0.100 |
Why?
|
Biopsy, Needle | 1 | 2018 | 1622 | 0.100 |
Why?
|
Neoplastic Stem Cells | 1 | 2021 | 1351 | 0.100 |
Why?
|
DNA Mutational Analysis | 1 | 2021 | 4120 | 0.100 |
Why?
|
Glomerular Filtration Rate | 1 | 2021 | 2227 | 0.100 |
Why?
|
Mutation | 5 | 2023 | 30238 | 0.100 |
Why?
|
Male | 19 | 2023 | 364719 | 0.100 |
Why?
|
Cross Infection | 1 | 2021 | 1426 | 0.100 |
Why?
|
Tissue Distribution | 1 | 2016 | 2300 | 0.100 |
Why?
|
Drug Interactions | 1 | 2016 | 1419 | 0.090 |
Why?
|
Uric Acid | 1 | 2017 | 805 | 0.090 |
Why?
|
Marital Status | 1 | 2012 | 426 | 0.090 |
Why?
|
Neoadjuvant Therapy | 2 | 2021 | 2907 | 0.090 |
Why?
|
Aniline Compounds | 1 | 2016 | 1094 | 0.090 |
Why?
|
Aged | 13 | 2023 | 171504 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2018 | 3556 | 0.080 |
Why?
|
Neoplasm Staging | 3 | 2021 | 11244 | 0.080 |
Why?
|
Venous Thromboembolism | 1 | 2022 | 1883 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2021 | 1942 | 0.080 |
Why?
|
Neovascularization, Pathologic | 1 | 2019 | 2631 | 0.080 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2022 | 8647 | 0.070 |
Why?
|
Tumor Microenvironment | 1 | 2021 | 3948 | 0.070 |
Why?
|
Middle Aged | 13 | 2023 | 223492 | 0.070 |
Why?
|
Bereavement | 1 | 2011 | 310 | 0.070 |
Why?
|
Sex Distribution | 1 | 2012 | 2278 | 0.070 |
Why?
|
Antibodies, Monoclonal | 1 | 2023 | 9263 | 0.070 |
Why?
|
Age Distribution | 1 | 2012 | 2873 | 0.070 |
Why?
|
Female | 12 | 2021 | 397192 | 0.070 |
Why?
|
Medical Oncology | 2 | 2022 | 2346 | 0.060 |
Why?
|
Chromosomes, Mammalian | 1 | 2006 | 148 | 0.060 |
Why?
|
Survival Analysis | 2 | 2021 | 10101 | 0.060 |
Why?
|
Educational Status | 1 | 2012 | 2515 | 0.060 |
Why?
|
Adaptation, Psychological | 2 | 2012 | 2663 | 0.060 |
Why?
|
NFATC Transcription Factors | 1 | 2006 | 393 | 0.060 |
Why?
|
Attitude to Health | 1 | 2012 | 2025 | 0.050 |
Why?
|
Treatment Outcome | 3 | 2018 | 65371 | 0.050 |
Why?
|
Models, Biological | 1 | 2019 | 9495 | 0.050 |
Why?
|
Quinuclidines | 1 | 2022 | 27 | 0.050 |
Why?
|
Clinical Trials as Topic | 1 | 2018 | 8054 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 10399 | 0.050 |
Why?
|
Tennessee | 1 | 2021 | 123 | 0.050 |
Why?
|
Receptors, Chemokine | 1 | 2004 | 652 | 0.050 |
Why?
|
Gene Dosage | 1 | 2006 | 1219 | 0.050 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2016 | 5341 | 0.040 |
Why?
|
Muscle, Skeletal | 2 | 2007 | 4978 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2016 | 13014 | 0.040 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2022 | 345 | 0.040 |
Why?
|
Muscle Proteins | 1 | 2006 | 1165 | 0.040 |
Why?
|
Adult | 9 | 2023 | 223646 | 0.040 |
Why?
|
Censuses | 1 | 2021 | 198 | 0.040 |
Why?
|
Grief | 2 | 2012 | 256 | 0.040 |
Why?
|
Boston | 1 | 2012 | 9374 | 0.040 |
Why?
|
Gene Fusion | 1 | 2022 | 356 | 0.040 |
Why?
|
Signal Transduction | 2 | 2021 | 23645 | 0.040 |
Why?
|
Decision Making | 1 | 2012 | 3953 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2022 | 560 | 0.040 |
Why?
|
Prognosis | 1 | 2019 | 30010 | 0.040 |
Why?
|
Survival Rate | 1 | 2012 | 12840 | 0.040 |
Why?
|
Risk Factors | 5 | 2021 | 74944 | 0.040 |
Why?
|
Workflow | 1 | 2022 | 860 | 0.040 |
Why?
|
Genetic Heterogeneity | 1 | 2021 | 736 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 710 | 0.040 |
Why?
|
Down Syndrome | 1 | 2006 | 919 | 0.040 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2021 | 465 | 0.040 |
Why?
|
Gene Expression | 2 | 2007 | 7598 | 0.030 |
Why?
|
Wound Healing | 1 | 2007 | 2809 | 0.030 |
Why?
|
Point Mutation | 1 | 2021 | 1596 | 0.030 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2006 | 2892 | 0.030 |
Why?
|
Regeneration | 1 | 2004 | 1524 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2359 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2021 | 998 | 0.030 |
Why?
|
Prevalence | 1 | 2012 | 15869 | 0.030 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2023 | 2062 | 0.030 |
Why?
|
Administration, Oral | 1 | 2022 | 4030 | 0.030 |
Why?
|
Warfarin | 1 | 2022 | 1493 | 0.030 |
Why?
|
Reference Values | 1 | 2021 | 4938 | 0.030 |
Why?
|
Immunohistochemistry | 2 | 2023 | 11095 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 2016 | 13676 | 0.030 |
Why?
|
Consensus | 1 | 2022 | 3212 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 20760 | 0.030 |
Why?
|
Young Adult | 2 | 2018 | 60066 | 0.030 |
Why?
|
DNA Copy Number Variations | 1 | 2021 | 2048 | 0.020 |
Why?
|
Mental Disorders | 1 | 2012 | 6874 | 0.020 |
Why?
|
Fluorouracil | 1 | 2017 | 1652 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2021 | 2810 | 0.020 |
Why?
|
Hemorrhage | 1 | 2022 | 3467 | 0.020 |
Why?
|
Risk Assessment | 2 | 2022 | 24315 | 0.020 |
Why?
|
Family Therapy | 1 | 2011 | 214 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2017 | 1667 | 0.020 |
Why?
|
Gene Expression Profiling | 2 | 2021 | 9538 | 0.020 |
Why?
|
Inpatients | 1 | 2021 | 2566 | 0.020 |
Why?
|
Mice | 5 | 2021 | 82029 | 0.020 |
Why?
|
Cohort Studies | 2 | 2021 | 41754 | 0.020 |
Why?
|
Hospices | 1 | 2011 | 245 | 0.020 |
Why?
|
Kidney | 1 | 2023 | 7064 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2006 | 11928 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2022 | 4648 | 0.020 |
Why?
|
Retrospective Studies | 3 | 2021 | 81762 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2021 | 3800 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2020 | 5536 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2018 | 6526 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2021 | 7608 | 0.020 |
Why?
|
Anticoagulants | 1 | 2022 | 4852 | 0.020 |
Why?
|
Genomics | 1 | 2022 | 5926 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2021 | 14729 | 0.020 |
Why?
|
Chromosomes, Human, Pair 21 | 1 | 2006 | 229 | 0.020 |
Why?
|
Computer Systems | 1 | 2007 | 469 | 0.020 |
Why?
|
Myogenin | 1 | 2004 | 54 | 0.020 |
Why?
|
Glucose | 1 | 2017 | 4352 | 0.020 |
Why?
|
Wounds, Penetrating | 1 | 2007 | 316 | 0.010 |
Why?
|
Pyrimidines | 1 | 2017 | 3048 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5367 | 0.010 |
Why?
|
Neural Cell Adhesion Molecules | 1 | 2004 | 122 | 0.010 |
Why?
|
MyoD Protein | 1 | 2004 | 143 | 0.010 |
Why?
|
Macrophage-1 Antigen | 1 | 2004 | 286 | 0.010 |
Why?
|
Freezing | 1 | 2004 | 311 | 0.010 |
Why?
|
Animals | 5 | 2021 | 169246 | 0.010 |
Why?
|
Receptors, CCR2 | 1 | 2004 | 216 | 0.010 |
Why?
|
Muscle Fibers, Skeletal | 1 | 2007 | 553 | 0.010 |
Why?
|
Time Factors | 2 | 2021 | 40218 | 0.010 |
Why?
|
Muscle Strength | 1 | 2007 | 640 | 0.010 |
Why?
|
Transgenes | 1 | 2006 | 1016 | 0.010 |
Why?
|
Muscle Contraction | 1 | 2007 | 1209 | 0.010 |
Why?
|
Coloring Agents | 1 | 2004 | 565 | 0.010 |
Why?
|
Myositis | 1 | 2004 | 269 | 0.010 |
Why?
|
Calcium-Binding Proteins | 1 | 2006 | 1083 | 0.010 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2017 | 3626 | 0.010 |
Why?
|
Hospitalization | 1 | 2021 | 10840 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8748 | 0.010 |
Why?
|
Fluorescent Antibody Technique | 1 | 2004 | 2474 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2017 | 17140 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 4580 | 0.010 |
Why?
|
Neovascularization, Physiologic | 1 | 2007 | 1369 | 0.010 |
Why?
|
Extracellular Matrix | 1 | 2007 | 1738 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2007 | 3800 | 0.010 |
Why?
|
Mental Health | 1 | 2012 | 3275 | 0.010 |
Why?
|
Fibrosis | 1 | 2004 | 2080 | 0.010 |
Why?
|
Mice, Inbred C57BL | 2 | 2007 | 22379 | 0.010 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2006 | 2433 | 0.010 |
Why?
|
Stress, Psychological | 1 | 2012 | 4530 | 0.010 |
Why?
|
Models, Genetic | 1 | 2006 | 3447 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2004 | 6082 | 0.010 |
Why?
|
Wounds and Injuries | 1 | 2007 | 2517 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2012 | 15948 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2006 | 9561 | 0.010 |
Why?
|
Adipose Tissue | 1 | 2004 | 3329 | 0.010 |
Why?
|
United States | 1 | 2020 | 73039 | 0.010 |
Why?
|
Depression | 1 | 2011 | 8230 | 0.010 |
Why?
|
Apoptosis | 1 | 2007 | 9523 | 0.010 |
Why?
|
Macrophages | 1 | 2004 | 5799 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2004 | 12800 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2004 | 14488 | 0.010 |
Why?
|
Phenotype | 1 | 2006 | 16726 | 0.000 |
Why?
|
Inflammation | 1 | 2007 | 10873 | 0.000 |
Why?
|
Disease Models, Animal | 1 | 2006 | 18349 | 0.000 |
Why?
|